Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.

• Phase: Phase 2

Details

• Lead Sponsor: Abbott
• Treatments: Amprenavir; Efavirenz; HIV Protease Inhibitors; Lopinavir; Protease Inhibitors; Ritonavir; Saquinavir